Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Urinary Bladder Neoplasms 10Non-Muscle Invasive Bladder Neoplasms 6Peritoneal Neoplasms 3Colorectal Neoplasms 3Carcinoma, Transitional Cell 3Appendiceal Neoplasms 3Anus Neoplasms 2Urothelial Carcinoma of the Bladder 1Urologic Neoplasms 1Urologic Diseases 1Urogenital Neoplasms 1Urogenital Diseases 1Urinary Bladder Diseases 1Rectal Neoplasms 1Pseudomyxoma Peritonei 1Peritoneal Diseases 1Ovarian Neoplasms 1Neoplasms by Site 1Neoplasms 1Necrosis 1Male Urogenital Diseases 1HIV Infections 1Gastrointestinal Neoplasms 1Female Urogenital Diseases 1Anal Canal Carcinoma 1

Interventions

pembrolizumab 22Nivolumab 14enfortumab vedotin 13Gemcitabine 11Specimen Handling 9Magnetic Resonance Spectroscopy 9Cisplatin 8Carboplatin 8sacituzumab govitecan 6avelumab 6Docetaxel 6atezolizumab 5Ipilimumab 5durvalumab 4Paclitaxel 4cabozantinib 3Taxes 3Mitomycin 3CTLA-4 Antigen 3tislelizumab 2relatlimab 2erdafitinib 2disitamab vedotin 2Radiosurgery 2Platinum 2Oxaliplatin 2Immunoglobulin G 2Fluorouracil 2Disulfides 2ALT-803 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Carcinoma, Transitional Cell × Mitomycin × 90 days × Clear all
NCT05243550 2026-05-11

ENVISION

UroGen Pharma Ltd.

Phase 3 Active not recruiting
240 enrolled 20 charts 1 FDA
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT07566156 2026-05-11

EV-309

Astellas Pharma Inc

Phase 3 Recruiting
390 enrolled
Genitourinary

Urogenital Diseases, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms, Female Urogenital Diseases, Male Urogenital Diseases

NCT06774131 2026-04-29

A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer

UroGen Pharma Ltd.

Phase 3 Recruiting
70 enrolled
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡